Mutant p53 gain of function is interwoven into the hallmarks of cancer

Journal of Pathology

Volumn 225, Issue 4, 2011, Pages 475-478

  Solomon, Hilla ^a   Madar, Shalom ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

angiogenesis; cyclin; head and neck; mouse model; oncogene addiction; p53; proliferation; ras

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER INVASION; CELL CYCLE ARREST; GAIN OF FUNCTION MUTATION; GENE ACTIVITY; GENOMIC INSTABILITY; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; METASTASIS; MITOSIS; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HEAD AND NECK NEOPLASMS; MUTATION;

EID: 81355154522     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2988     Document Type: Review

References (41)

1. Brosh R, Rotter V,. When mutants gain new powers: news from the mutant p53 field. Nature Rev Cancer 2009; 9: 701-713.
2. Goh AM, Coffill CR, Lane DP,. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
3. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
4. Madar S, Goldstein I, Rotter V,. Did experimental biology die? Lessons from 30 years of p53 research. Cancer Res 2009; 69: 6378-6380.
5. Acin S, Li Z, Mejia O, et al., Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 2011; 225: 479-489.
6. Peled A, Zipori D, Rotter V,. Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res 1996; 56: 2148-2156.
7. Li R, Sutphin PD, Schwartz D, et al., Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998; 16: 3269-3277.
8. Blandino G, Levine AJ, Oren M,. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-485.
9. Weisz L, Damalas A, Liontos M, et al., Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 2007; 67: 2396-2401.
10. Buganim Y, Kalo E, Brosh R, et al., Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res 2006; 66: 10750-10759.
11. Stambolsky P, Tabach Y, Fontemaggi G, et al., Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17: 273-285.
12. Di Agostino S, Strano S, Emiliozzi V, et al., Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
13. Brosh R, Rotter V,. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Mol Biosyst 2010; 6: 17-29.
14. Liu DP, Song H, Xu Y,. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010; 29: 949-956.
15. Song H, Hollstein M, Xu Y,. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biol 2007; 9: 573-580.
16. Murphy KL, Rosen JM,. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene 2000; 19: 1045-1051.
17. Muller PA, Caswell PT, Doyle B, et al., Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
18. Xia M, Land H,. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nature Struct Mol Biol 2007; 14: 215-223.
19. Lee JM, Dedhar S, Kalluri R, et al., The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
20. Kogan-Sakin I, Tabach Y, Buganim Y, et al., Mutant p5 rm{R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011; 18: 271-281.
21. Wang SP, Wang WL, Chang YL, et al., p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nature Cell Biol 2009; 11: 694-704.
22. Dhar G, Banerjee S, Dhar K, et al., Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 2008; 68: 4580-4587.
23. Zhang Y, Yan W, Chen X,. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem 2011; 286: 16218-16228.
24. Olive KP, Tuveson DA, Ruhe ZC, et al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
25. Lang GA, Iwakuma T, Suh YA, et al., Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
26. Caulin C, Nguyen T, Lang GA, et al., An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 2007; 117: 1893-1901.
27. Doyle B, Morton JP, Delaney DW, et al., p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 2010; 222: 129-137.
28. Heinlein C, Krepulat F, Lohler J, et al., Mutant p53 R270H gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 2008; 122: 1701-1709.
29. G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
30. Morton JP, Timpson P, Karim SA, et al., Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010; 107: 246-251.
31. Addadi Y, Moskovits N, Granot D, et al., p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 2010; 70: 9650-9658.
32. Tian Y, Ding RY, Zhi YH, et al., Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006; 12: 415-419.
33. Famulski W, Sulkowska M, Wincewicz A, et al., P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 2006; 53: 43-48.
34. Fontemaggi G, Dell'Orso S, Trisciuoglio D, et al., The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nature Struct Mol Biol 2009; 16: 1086-1093.
35. McMurray HR, Sampson ER, Compitello G, et al., Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 2008; 453: 1112-1116.
36. Buganim Y, Solomon H, Rais Y, et al., p53 regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res 2010; 70: 2274-2284.
37. Perkins ND,. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nature Rev Mol Cell Biol 2007; 8: 49-62.
38. Scian MJ, Stagliano KE, Anderson MA, et al., Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 2005; 25: 10097-10110.
39. Malkin D, Li FP, Strong LC, et al., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
40. Weinstein IB,. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-64.
41. Weinstein IB, Joe A,. Oncogene addiction. Cancer Res 2008; 68: 3077-3080; discussion 3080.